Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G1RH
|
|||
| Former ID |
DIB010796
|
|||
| Drug Name |
NPS-2143
|
|||
| Synonyms |
NPS-2143; 284035-33-2; NPS 2143; NPS2143; UNII-Z25PJ77W7V; SB-262470; Z25PJ77W7V; CHEMBL180672; 2-CHLORO-6-[(2R)-3-[[1,1-DIMETHYL-2-(2-NAPHTHALENYL)ETHYL]AMINO]-2-HYDROXYPROPOXY]BENZONITRILE; C24H25ClN2O2; 2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile; (R)-2-chloro-6-(2-hydroxy-3-((2-methyl-1-(naphthalen-2-yl)propan-2-yl)amino)propoxy)benzonitrile; SB-262470A; (+)-NPS-2143; AC1OCFG2; GTPL716; SCHEMBL13597018; EX-A017; DTXSID10426075; MolPort-021-805-006; BCPP000077; ZINC3975668
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Discontinued in Phase 2 | [1], [2] | |
| Company |
NPS Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H25ClN2O2
|
|||
| Canonical SMILES |
CC(C)(CC1=CC2=CC=CC=C2C=C1)NCC(COC3=C(C(=CC=C3)Cl)C#N)O
|
|||
| InChI |
1S/C24H25ClN2O2/c1-24(2,13-17-10-11-18-6-3-4-7-19(18)12-17)27-15-20(28)16-29-23-9-5-8-22(25)21(23)14-26/h3-12,20,27-28H,13,15-16H2,1-2H3/t20-/m1/s1
|
|||
| InChIKey |
PZUJQWHTIRWCID-HXUWFJFHSA-N
|
|||
| CAS Number |
CAS 284035-33-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12015260, 14855237, 17194894, 43529816, 49888603, 50232180, 57371933, 103443095, 104047510, 114787986, 121280058, 124360780, 125164693, 126646528, 126671455, 134342083, 135650739, 136340370, 136349529, 136367660, 136367790, 142774442, 152258052, 152343807, 160646890, 162011657, 162038035, 162202765, 164023450, 174006304, 184823472, 198959006, 223369937, 223395496, 223666833, 238590854, 242589476, 246492847, 252220157
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular calcium-sensing receptor (CASR) | Target Info | Antagonist | [3] |
| Pathway Interaction Database | E-cadherin signaling in keratinocytes | |||
| Reactome | G alpha (q) signalling events | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 716). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010915) | |||
| REF 3 | Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.